<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03626207</url>
  </required_header>
  <id_info>
    <org_study_id>CLR180001</org_study_id>
    <nct_id>NCT03626207</nct_id>
  </id_info>
  <brief_title>Development of Visual Function Evaluation Method (2)</brief_title>
  <official_title>Calibration of Visual Function Evaluation Tests in Patients With Severe Vision Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to develop the comprehensive visual function evaluation method
      in severe visually impaired patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Slit-lamp-microscopy</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Optical Coherence Tomography (OCT) test</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Early Treatment Diabetic Retinopathy Study (ETDRS)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>NEI VFQ 25 is a questionnaire intended to measure visual function and quality of life. It has 25 questions. The original response of each item are coded as per the NEI VFQ scoring system ranging from 0 (worst) to 100 (best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The 11-item National Eye Institute Visual Function Questionnaire (NEI VFQ-11)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>NEI VFQ 11 is a questionnaire intended to measure visual function and quality of life. It has 11 questions. The original response of each item are coded as per the NEI VFQ scoring system ranging from 0 (worst) to 100 (best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nottingham Adjustment Scale Japanese Version (NAS-J)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>NAS-J is the Japanese version of NAS which measures psychological adjustment to the visual impairment, and to assess its validity and reliability. The NAS is composed of 7 psychological subscales including anxiety-depression, self-esteem, attitude to disability, locus of control, acceptance of disability, self-efficacy and attributional style. The original response of each item are coded as per the NAS-J scoring system ranging from 0 (lowest psychological adjustment) to 100 (highest psychological adjustment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily living task dependent on vision (DLTV) questionnaire</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>DLTV is a quality of life questionnaire composed of 22 items to obtain estimates of self-reported ability to perform vision-related tasks in persons with visual impairment. Participants rate items on a four-point scale, with &quot;Can't see to do&quot; (score, 1), &quot;A lot of difficulty&quot; (score, 2), &quot;A little difficulty&quot; (score, 3), and&quot;No difficulty&quot; (score, 4). The original response of each item are coded as per the DLTV scoring system ranging from 0 (worst) to 100 (best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Table test</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Monitor test</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pupillary function test</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Full field stimulus threshold testing (FST)</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White flash visual evoked potential (VEP) test</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Color flash VEP test</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrically evoked response (EER) test</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White flash Electroretinography (ERG) test</measure>
    <time_frame>Day 1</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multifocal ERG test</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To assess the visual function.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Retinitis pigmentosa</arm_group_label>
    <description>Retinitis pigmentosa patients with severe visual impairment</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Retinitis pigmentosa
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with severe visual disturbance (count-fingers or worse vision for severe
             eyes) at the time of obtaining the consent and at screening

        Exclusion Criteria:

          -  Subjects should not have participated in any other clinical trial or clinical study
             involving visual function evaluation within 6 months

          -  History of surgery, past history, and complications (cardiac/ hepatic/ renal/
             respiratory/ hematological diseases, optic nerve diseases causing marked loss of
             visual field, and uveitis etc.) that potentially affect evaluation and safety of the
             study

          -  Pregnant women

          -  Subjects who are judged that continuation of the study is difficult during the study
             period

          -  Subjects who are employed by the company sponsoring this study, an organization or
             institution related to this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinitis pigmentosa</keyword>
  <keyword>Visual function evaluation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual patient level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Information for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

